

PTO/PCT Rec'd 23 NOV 2001

#3

Atty. No. 033236-0114

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Karen AKINSANYA et al.

Title: LHRH ANALOGUES FOR THE
TREATMENT OF OSTEOPOROSIS

Appl. No.: 09/830,343

Filing Date: 04/26/2001

Examiner: Unassigned

Art Unit: Unassigned



INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box IDS
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 23 November 2001

By

S. A. Bent

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
033236-0114SERIAL NO.
09/830,343

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Karen AKINSANYA et al.

FILING DATE

04/26/2001

GROUP ART UNIT

Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,091,367	2/92	Konig et al.	514	15	
	A2	4,721,755	1/88	Folkers et al.	530	313	
	A3	4,540,513	9/85	Miyamoto	260	112.5R	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	B1	WO91/05563	5/91	WIPO	A61K37/02	C07K7/06		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	B2	Paoletti, A. M., et al., JOURNAL ARTICLE, "Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment", April 1996.
	B3	White, R. B., et al., MEDICAL SCIENCES, "Second gene for gonadotropin-releasing hormone in humans", Proc. Natl. Acad. Sci., Vol. 95 pp. 305-309, January 1998

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.